Vosaroxin for relapsed AML: Updates from VALOR

Share :
Published: 5 Dec 2016
Views: 2131
Rating:
Save
Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

Dr Ravandi speaks with ecancertv at ASH 2016 with updates from the VALOR trial of vosaroxin versus placebo in combination with cytarabine. 

These results, first reported at ASH 2014, position vosaroxin as a major step forward for elderly patients with relapsed or refractory acute myeloid leukaemia based on its subversion of known resistance pathways.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.